ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma.

Saved in:
Bibliographic Details
Title: ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma.
Authors: Megino-Luque C; Oncologic Pathology Group, Department of Medicine and Surgery, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain. cristina.meginoluque@mssm.edu.; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. cristina.meginoluque@mssm.edu.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. cristina.meginoluque@mssm.edu., Albertí-Valls M; Oncologic Pathology Group, Department of Medicine and Surgery, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain., Olave S; Oncologic Pathology Group, Department of Medicine and Surgery, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Sisó P; Oncologic Pathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain., Bonifaci N; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via De l'Hospitalet 199, Barcelona, Spain., Macià A; Oncologic Pathology Group, Department of Experimental Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain., Matias-Guiu X; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain., Gatius S; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.; Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain., Llobet-Navas D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Gran via De l'Hospitalet 199, Barcelona, Spain., Eritja N; Oncologic Pathology Group, Department of Medicine and Surgery, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Lleida, Spain. nuria.eritja@udl.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. nuria.eritja@udl.cat.
Source: Cell death & disease [Cell Death Dis] 2026 Apr 10; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 10.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-4889
DOI:10.1038/s41419-026-08723-z